Resverlogix’ BETonMACE phase 3 trial successfully reaches its targeted 250 MACE events
Resverlogix announces that BETonMACE, the Company’s event-based, phase 3 registration trial has successfully reached 250 projected major adverse cardiac eventsm moving the trial towards completion. Successful data from this trial would enable Resverlogix to proceed towards regulatory approval. April 18, 2019